Tryptamine secures $6m for IV psilocin drug
Tryptamine has firm commitments to raise $6m in a placement to advance clinical development of its novel IV-infused psilocin formulation TRP-8803.
Tryptamine has firm commitments to raise $6m in a placement to advance clinical development of its novel IV-infused psilocin formulation TRP-8803.
Li-S Energy’s commercial potential has lifted after the company successfully completed drone test flights powered by a 12-cell lithium sulfur battery pack.
Ground electromagnetic surveying at Koonenberry’s Atlantis copper-gold prospect is aimed at finding potential sulphides.
Stockhead host Sarah Hughan welcomes GTI Energy executive director and CEO Bruce Lane to the studio.
Airtasker has continued to deliver positive financial news with Q1 FY25 free cash flow of $100k and operating cash flow of $900k, up 31.6% on pcp.
Moomoo reveals its most-traded October securities as US election trades and China ETFs take a dominant role.
BlinkLab will participate in the MAGNET project, which aims to study 1000 families with children diagnosed with only autism, only ADHD, or both.
Thicker, higher-grade gold, silver and copper intersections will feed into the maiden resource estimate for Challenger Gold’s Colorado-V project in Ecuador.
Bank stocks have fallen on the ASX on Wednesday, with gold dipping below $US2600. The news has been better for Nvidia, as it hit record highs.
New Age Exploration’s resampling work has reinforced the gold potential of its Wagyu project and confidence in its targeting approach and exploration strategy
Octava Minerals’ drill program will test the Discovery target, where historical drilling has intersected high-grade antimony, and the undrilled Central target.
A 6000m RC drilling program is underway at the Montague East gold project, targeting depth extensions of two large deposits
Host Fraser Palamara explains the major autism and ADHD study BlinkLab is getting involved in with Melbourne’s Monash University.
A mix of good luck and good planning is set to pay off for Botanix – with its FDA-approved drug to treat excessive sweating in the process of a ‘soft’ US launch.
Original URL: https://www.goldcoastbulletin.com.au/business/stockhead/page/9